NASDAQ · NCEL
Healthcare · Biotechnology
$3.38
Down-$0.01 (-0.29%)
Updated Sep 18, 2026, 7:06 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NCEL closed at $3.38 after 20 trading sessions, up 0.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $3.295 | $3.39 | $3.15 | $3.38 | 12.19K |
| Sep 16, 2026 | $3.2927 | $3.40 | $3.14 | $3.39 | 4.64K |
| Sep 15, 2026 | $3.35 | $3.35 | $3.31 | $3.32 | 2.78K |
| Sep 14, 2026 | $3.28 | $3.31 | $3.225 | $3.28 | 6.84K |
| Sep 11, 2026 | $3.30 | $3.3237 | $3.2239 | $3.3045 | 3.75K |
| Sep 10, 2026 | $3.29 | $3.4999 | $3.25 | $3.38 | 5.72K |
| Sep 9, 2026 | $3.16 | $3.30 | $3.16 | $3.25 | 3.51K |
| Sep 8, 2026 | $3.235 | $3.35 | $3.22 | $3.25 | 4.21K |
| Sep 4, 2026 | $3.37 | $3.37 | $3.24 | $3.35 | 1.41K |
| Sep 3, 2026 | $3.4583 | $3.50 | $3.1473 | $3.35 | 9.01K |
| Sep 2, 2026 | $3.39 | $3.39 | $3.33 | $3.35 | 3.51K |
| Sep 1, 2026 | $3.21 | $3.29 | $3.21 | $3.29 | 1.86K |
| Aug 31, 2026 | $3.40 | $3.40 | $3.23 | $3.275 | 13.87K |
| Aug 28, 2026 | $3.37 | $3.3701 | $3.19 | $3.19 | 12.44K |
| Aug 27, 2026 | $3.27 | $3.51 | $3.27 | $3.42 | 19.98K |
| Aug 26, 2026 | $3.44 | $3.5139 | $3.30 | $3.38 | 18.83K |
| Aug 25, 2026 | $3.50 | $3.60 | $3.31 | $3.48 | 17.03K |
| Aug 24, 2026 | $3.40 | $3.50 | $3.325 | $3.46 | 6.12K |
| Aug 21, 2026 | $3.31 | $3.31 | $3.2153 | $3.2627 | 1.4K |
| Aug 20, 2026 | $3.25 | $3.40 | $3.17 | $3.37 | 9.43K |
The latest Smart Investors Daily articles mentioning NCEL.
NCEL research
Company profile and research snapshot.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Laidlaw & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 15, 2026
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent
Benzinga · Jul 13, 2026
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating and announces Price Target of $23.
Benzinga · Jul 1, 2026
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an
Benzinga · Jun 15, 2026
The publication further validates NewcelX's ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications.The full paper
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NCEL.
